| Autor: |
Fabbri, Leonardo M., Calverley, Peter M. A., Jose Luis Izquierdo Alonso, Bundschuh, Daniela S., Manja, Brose, Martinez, Fernando J., Rabe, Kf M., Study Groups Abdulla, M., Abdullah, I., Adler, M., Aguilaniu, Albert, I., Almonacid, C., Altés, A., Amaducci, S., Angrill, J., Antonana, J. M., Artner, H., Balint, B., Bantje, T. A., Barbe, F., Bateman, E., Bauchnect, E., Belda, J., Bernabeu, L., Bettendorf, A., Blagden, M., Blanquer, R., Blecher, L., Bonnaud, F., Bourbeau, J., Boyer, G. R., Brotons, C., Bruning, A. H., Bucca, C., Burns, G. E., Von Der Heydt, B. B., Caldwell, Canonica, G. W., Carter, J., Chan, V., Chapman, K. R., Chapman, G., Cheung, D., Chiner, E., Chopra, A., Clini, E., Coulet, P., Craig, B., Croonenborghs, L., Czompó, M., Dal Negro, R. W., Dapper, T., De Graaff, C. S., Ramos Pde, L., De Munck, D. R., Decramer, M., Delobbe, A., Denier, W., De Teresa, L., Dhar, A., Di Maria, G., Dupouy, J., Duschek, G., Echave, J., Esteban, C., Farmer, I. S., Flemale, A., Fletcher, P., Foden, Fouquert, L., Franz, K. H., Frognier, Gagnon, M., Garcia, Mdel M., Garelli, G., Gehling, U., Ginko, T., Glekin, B., Gooding, T., Graham, A., Greillier, P., Greses, J. V., Grillenberger, J., Gross, B., Grygier, H., Gyori, Z., Harper, Henein, S., Heredia, J. L., Hernandez, P., Hoefer, M., Hoffstein, V., Holgate, K., Holler, W., Holub, G., Homik, L., Houle, P. A., Hutter, C., Hyvernat, P., Irusen, E. M., Jackson, A., Janisty, W., Jasnot, J. Y., Joubert, J., Juhasz, G., Jullian, H., Kafe, H., Kelly, P., Kidney, J., Killian, K., Kinch, H., Kirsten, D. L., Kleinecke Pohl, U., Korlipara, K., Krige, L. P., Kroker, A., Kuipers, A. F., Labrecque, M., Larivee, P., Laskowitz, C., Le Merre, C., Lemoigne, F., Ludwig Sengpiel, A., Luengo, M., Luton, R., Macnee, W., Ali, S. M., Maltais, F., Mansur, A., Marciniuk, D., Marin, A., Martin, P., Martinot, J. B., Mazza, F., Bride, M. C., Mcdonald, B., Mckinnon, C., Mclvor, A., Mcnally, D., Mengeot, P. M., Messner, J., Moder, G., Mooney, P., Moretti, A. M., Muller, D., Murio, C., Nardini, S., Nel, A., Ochoa, Saracho Jo, D. E., Paggiaro, P., Paradis, B., Patrick, J., Peche, R., Pellicer, C., Perez, T., Perez, E., De Llano, L. A., Philteos, G., Pieters, W. R., Pigearias, B., Pohl, W., Popovic, R., Prins, M., Querfurt, H., Rajkay, K., Ras, G., Road, J., Roig, J., Roldaan, A. C., Rolke, M., Rozen, D., Sanchez Toril, F., Savani, N., Savary, L., Schiavina, M., Schiesbühl, H., Schreurs, A. J., Schröder Babo, W., Schurmann, W., Seiz, V., Sevette, C., Sharma, R., Shum, C., Damsté, H. E., Smithers, A., Soler, J. J., Steffen, H., Steinhauser, U., Sweilem, M., Tellier, G., Terol, B., Terzano, Claudio, Timar, M., Toma, G., Monserrat, P. T., Trauth, H. A., Valyon, E., Brande Van Den, Van Noord, J. A., Vaquer, J. V., Hernandez Hector, H. V., Vereecken, G., Verkindre, C., Vigh, M., Viljoen, J. J., Vincken, W., Vinkler, I., Visser, S., Volgmann, L., Vorderstrasse, W., Voves, R., Vrancken, F., Weber, H. H., Wielders, P. L., Willoughby, P., Wurtz, J., Yang, W., Zabaleta, M., Zachgo, W., Zanini, A., Zeiner, M., Michael, H., Janistyn, W., Abdulla, R., Terzano, C., Fabbri, L., Barbaro, M. P., Izquierdo, J. L., Ramos, Pde L., Harper, Ochoa |
| Rok vydání: |
2009 |
| Předmět: |
|
| Zdroj: |
The Lancet. 374:695-703 |
| ISSN: |
0140-6736 |
| DOI: |
10.1016/s0140-6736(09)61252-6 |
| Popis: |
Summary Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. Methods In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral roflumilast 500 μg or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1 s (FEV 1 ). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, number NCT00313209 for M2-127, and NCT00424268 for M2-128. Findings In the salmeterol plus roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium plus roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean prebronchodilator FEV 1 by 49 mL (p 1 was noted in both groups. Furthermore, roflumilast had beneficial effects on other lung function measurements and on selected patient-reported outcomes in both groups. Nausea, diarrhoea, weight loss, and, to a lesser extent, headache were more frequent in patients in the roflumilast groups. These adverse events were associated with increased patient withdrawal. Interpretation Roflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients. Funding Nycomed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
